… ProQR Announces Presentation on its Axiomer™ RNA Editing … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … Development” This presentation will provide an overview of ProQR’s proprietary ADAR-mediated Axiomer RNA editing …
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… ProQR Announces Webcast of Presentation at Upcoming HC … on demand from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under ‘Events’, beginning March 9, 2021. …
… ProQR Announces Recent Progress and Financial Results for the … & CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … said Daniel A. de Boer, chief executive officer of ProQR. “In October we announced that LCA10 patients …
… ProQR to Present at Cowen and Company 40th Annual Health Care … will be accessible from the “Investors” section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
… ProQR Announces Publication in Nature Medicine for Sepofarsen … & CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR ), a company dedicated … vision,” said Aniz Girach, MD, Chief Medical Officer of ProQR, “The visual field improvements observed indicate that …
… ProQR to Present at the Leerink Partners 4th Annual Rare … be accessible from the 'Investor Relations' section of ProQR's website ( www.proqr.com ) under 'Events and Presentations'. The …